---
document_datetime: 2025-12-02 04:52:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi.html
document_name: vitrakvi.html
version: success
processing_time: 0.1117477
conversion_datetime: 2025-12-26 19:16:44.978254
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vitrakvi

[RSS](/en/individual-human-medicine.xml/67244)

##### Authorised

This medicine is authorised for use in the European Union

larotrectinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vitrakvi](#news-on)
- [More information on Vitrakvi](#more-information-on-vitrakvi-898)
- [More information on Vitrakvi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vitrakvi is a cancer medicine for treating solid tumours with NTRK gene fusion. NTRK gene fusion is a rare genetic abnormality that can occur in tumours from different parts of the body such as the lungs, thyroid glands and intestines.

Vitrakvi is used in patients whose tumours are advanced, have spread to other parts of the body or are not amenable to surgery, and who have no satisfactory alternative treatments.

It contains the active substance larotrectinib.

Expand section

Collapse section

## How is Vitrakvi used?

Vitrakvi is available as a liquid (20 mg per ml) and capsules (25 and 100 mg) and is taken by mouth. Adult patients should take 100 mg twice a day for as long as the cancer is stable and the side effects are acceptable. The dose for children is based on their body surface area (weight and height).

Vitrakvi should be started by a doctor experienced in using cancer medicines and can only be obtained with a prescription. For more information about using Vitrakvi, see the package leaflet or contact your doctor or pharmacist.

## How does Vitrakvi work?

Tumours with NTRK gene fusion produce an abnormal protein (TRK fusion protein), which causes the uncontrolled growth of cancer cells. The active substance in Vitrakvi, larotrectinib, blocks the action of this protein, preventing the excessive growth of cancer cells and thereby slowing down the worsening of the cancer.

## What benefits of Vitrakvi have been shown in studies?

Three ongoing studies in 102 patients with solid tumours with NTRK gene fusion showed that Vitrakvi is effective at reducing the size of patients' tumours. In these studies, 67% of patients who took Vitrakvi had a reduction in the size of their tumours, and the tumours on average shrank to less than half their original size. In addition, the tumours shrank quickly (within 2 months).

## What are the risks associated with Vitrakvi?

The most common side effects with Vitrakvi (which may affect more than 1 in 5 people) are tiredness, dizziness, constipation, nausea, vomiting, anaemia (low red blood cell counts) and high blood levels of alanine aminotransferase and aspartate aminotransferase (a sign of liver problems).

Most side effects are mild to moderate. For the full list of side effects and restrictions, see the package leaflet.

## Why is Vitrakvi authorised in the EU?

Vitrakvi differs from many other cancer medicines by targeting certain tumours with a specific gene arrangement wherever they occur in the body. Although studies are still underway, the results released so far show that it is effective at reducing the size of patients' tumours. In addition, the short time taken to shrink the tumours is important in relieving patients' symptoms.

As for its safety, the side effects of Vitrakvi appear manageable. The European Medicines Agency therefore concluded that its benefits are greater than its risks and that it can be authorised for use in the EU.

Vitrakvi has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Vitrakvi?

Since Vitrakvi has been given conditional authorisation, the company that markets Vitrakvi will provide further data on its effects. This data will come from the three ongoing studies which aim to confirm the benefits and safety of Vitrakvi and its longer term effect in children.

## What measures are being taken to ensure the safe and effective use of Vitrakvi?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vitrakvi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vitrakvi are continuously monitored. Side effects reported with Vitrakvi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vitrakvi

Vitrakvi received a conditional marketing authorisation valid throughout the EU on 19 September 2019.

Vitrakvi : EPAR - Medicine overview

Reference Number: EMA/457887/2019

English (EN) (74.59 KB - PDF)

**First published:** 24/10/2019

[View](/en/documents/overview/vitrakvi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-909)

български (BG) (101.03 KB - PDF)

**First published:**

24/10/2019

[View](/bg/documents/overview/vitrakvi-epar-medicine-overview_bg.pdf)

español (ES) (73.6 KB - PDF)

**First published:**

24/10/2019

[View](/es/documents/overview/vitrakvi-epar-medicine-overview_es.pdf)

čeština (CS) (96.24 KB - PDF)

**First published:**

24/10/2019

[View](/cs/documents/overview/vitrakvi-epar-medicine-overview_cs.pdf)

dansk (DA) (72.68 KB - PDF)

**First published:**

24/10/2019

[View](/da/documents/overview/vitrakvi-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.24 KB - PDF)

**First published:**

24/10/2019

[View](/de/documents/overview/vitrakvi-epar-medicine-overview_de.pdf)

eesti keel (ET) (72.28 KB - PDF)

**First published:**

24/10/2019

[View](/et/documents/overview/vitrakvi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (109.21 KB - PDF)

**First published:**

24/10/2019

[View](/el/documents/overview/vitrakvi-epar-medicine-overview_el.pdf)

français (FR) (74.87 KB - PDF)

**First published:**

24/10/2019

[View](/fr/documents/overview/vitrakvi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (91.19 KB - PDF)

**First published:**

24/10/2019

[View](/hr/documents/overview/vitrakvi-epar-medicine-overview_hr.pdf)

italiano (IT) (72.68 KB - PDF)

**First published:**

24/10/2019

[View](/it/documents/overview/vitrakvi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (94.34 KB - PDF)

**First published:**

24/10/2019

[View](/lv/documents/overview/vitrakvi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (95.05 KB - PDF)

**First published:**

24/10/2019

[View](/lt/documents/overview/vitrakvi-epar-medicine-overview_lt.pdf)

magyar (HU) (91.91 KB - PDF)

**First published:**

24/10/2019

[View](/hu/documents/overview/vitrakvi-epar-medicine-overview_hu.pdf)

Malti (MT) (104.02 KB - PDF)

**First published:**

24/10/2019

[View](/mt/documents/overview/vitrakvi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.24 KB - PDF)

**First published:**

24/10/2019

[View](/nl/documents/overview/vitrakvi-epar-medicine-overview_nl.pdf)

polski (PL) (98.33 KB - PDF)

**First published:**

24/10/2019

[View](/pl/documents/overview/vitrakvi-epar-medicine-overview_pl.pdf)

português (PT) (74.58 KB - PDF)

**First published:**

24/10/2019

[View](/pt/documents/overview/vitrakvi-epar-medicine-overview_pt.pdf)

română (RO) (94.54 KB - PDF)

**First published:**

24/10/2019

[View](/ro/documents/overview/vitrakvi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.77 KB - PDF)

**First published:**

24/10/2019

[View](/sk/documents/overview/vitrakvi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.9 KB - PDF)

**First published:**

24/10/2019

[View](/sl/documents/overview/vitrakvi-epar-medicine-overview_sl.pdf)

Suomi (FI) (72.65 KB - PDF)

**First published:**

24/10/2019

[View](/fi/documents/overview/vitrakvi-epar-medicine-overview_fi.pdf)

svenska (SV) (66.72 KB - PDF)

**First published:**

24/10/2019

[View](/sv/documents/overview/vitrakvi-epar-medicine-overview_sv.pdf)

Vitrakvi : EPAR - Risk management plan

English (EN) (1.98 MB - PDF)

**First published:** 27/08/2024

[View](/en/documents/rmp/vitrakvi-epar-risk-management-plan_en.pdf)

## Product information

Vitrakvi : EPAR - Product information

English (EN) (980.57 KB - PDF)

**First published:** 24/10/2019

**Last updated:** 04/08/2025

[View](/en/documents/product-information/vitrakvi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-805)

български (BG) (1.1 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/bg/documents/product-information/vitrakvi-epar-product-information_bg.pdf)

español (ES) (1 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/es/documents/product-information/vitrakvi-epar-product-information_es.pdf)

čeština (CS) (1.05 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/cs/documents/product-information/vitrakvi-epar-product-information_cs.pdf)

dansk (DA) (970.49 KB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/da/documents/product-information/vitrakvi-epar-product-information_da.pdf)

Deutsch (DE) (1.04 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/de/documents/product-information/vitrakvi-epar-product-information_de.pdf)

eesti keel (ET) (1 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/et/documents/product-information/vitrakvi-epar-product-information_et.pdf)

ελληνικά (EL) (1.07 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/el/documents/product-information/vitrakvi-epar-product-information_el.pdf)

français (FR) (1.08 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/fr/documents/product-information/vitrakvi-epar-product-information_fr.pdf)

hrvatski (HR) (1.04 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/hr/documents/product-information/vitrakvi-epar-product-information_hr.pdf)

íslenska (IS) (1006.03 KB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/is/documents/product-information/vitrakvi-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/it/documents/product-information/vitrakvi-epar-product-information_it.pdf)

latviešu valoda (LV) (1.06 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/lv/documents/product-information/vitrakvi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.05 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/lt/documents/product-information/vitrakvi-epar-product-information_lt.pdf)

magyar (HU) (1.1 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/hu/documents/product-information/vitrakvi-epar-product-information_hu.pdf)

Malti (MT) (1.07 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/mt/documents/product-information/vitrakvi-epar-product-information_mt.pdf)

Nederlands (NL) (1.05 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/nl/documents/product-information/vitrakvi-epar-product-information_nl.pdf)

norsk (NO) (976.28 KB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/no/documents/product-information/vitrakvi-epar-product-information_no.pdf)

polski (PL) (1.06 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/pl/documents/product-information/vitrakvi-epar-product-information_pl.pdf)

português (PT) (1.01 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/pt/documents/product-information/vitrakvi-epar-product-information_pt.pdf)

română (RO) (1.08 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/ro/documents/product-information/vitrakvi-epar-product-information_ro.pdf)

slovenčina (SK) (1.08 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/sk/documents/product-information/vitrakvi-epar-product-information_sk.pdf)

slovenščina (SL) (1.05 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/sl/documents/product-information/vitrakvi-epar-product-information_sl.pdf)

Suomi (FI) (1.05 MB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/fi/documents/product-information/vitrakvi-epar-product-information_fi.pdf)

svenska (SV) (1005.54 KB - PDF)

**First published:**

24/10/2019

**Last updated:**

04/08/2025

[View](/sv/documents/product-information/vitrakvi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000286907 04/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vitrakvi : EPAR - All authorised presentations

English (EN) (54.73 KB - PDF)

**First published:** 21/08/2020

**Last updated:** 12/05/2021

[View](/en/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-154)

български (BG) (70.61 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/bg/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.29 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/es/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.23 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/cs/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (71.63 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/da/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (53.71 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/de/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (69.27 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/et/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (87.1 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/el/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_el.pdf)

français (FR) (52.14 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/fr/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (105.78 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/hr/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (72.03 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/is/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.57 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/it/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.18 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/lv/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (72.45 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/lt/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (75.75 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/hu/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (76.13 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/mt/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.39 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/nl/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (73.78 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/no/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_no.pdf)

polski (PL) (77.28 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/pl/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.83 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/pt/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_pt.pdf)

română (RO) (85.54 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/ro/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (71.81 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/sk/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (79.68 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/sl/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (50.96 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/fi/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (74.93 KB - PDF)

**First published:**

21/08/2020

**Last updated:**

12/05/2021

[View](/sv/documents/all-authorised-presentations/vitrakvi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vitrakvi Active substance larotrectinib sulfate International non-proprietary name (INN) or common name larotrectinib Therapeutic area (MeSH) Abdominal Neoplasms Anatomical therapeutic chemical (ATC) code L01XE53

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options.

## Authorisation details

EMA product number EMEA/H/C/004919

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Bayer AG

51368 Leverkusen

Opinion adopted 25/07/2019 Marketing authorisation issued 19/09/2019 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vitrakvi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.79 KB - PDF)

**First published:** 24/07/2025

**Last updated:** 04/08/2025

[View](/en/documents/procedural-steps-after/vitrakvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vitrakvi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (154.59 KB - PDF)

**First published:** 31/07/2020

**Last updated:** 24/07/2025

[View](/en/documents/procedural-steps-after/vitrakvi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vitrakvi-H-C-004919-P46-008 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/26478/2023

English (EN) (1.93 MB - PDF)

**First published:** 05/04/2023

[View](/en/documents/variation-report/vitrakvi-h-c-004919-p46-008-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Vitrakvi : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/397644/2019

English (EN) (230.13 KB - PDF)

**First published:** 24/10/2019

[View](/en/documents/orphan-maintenance-report/vitrakvi-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Vitrakvi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/469135/2019

English (EN) (9.82 MB - PDF)

**First published:** 24/10/2019

[View](/en/documents/assessment-report/vitrakvi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vitrakvi

Adopted

Reference Number: EMA/CHMP/413258/2019

English (EN) (103.87 KB - PDF)

**First published:** 26/07/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vitrakvi_en.pdf)

#### News on Vitrakvi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019) 26/07/2019

[First 'histology-independent' treatment for solid tumours with a specific gene mutation](/en/news/first-histology-independent-treatment-solid-tumours-specific-gene-mutation) 26/07/2019

#### More information on Vitrakvi

This product is no longer an orphan medicine. It was originally designated an orphan medicine for the following orphan indications:

- [treatment of soft tissue sarcoma](/en/medicines/human/orphan-designations/eu-3-15-1606) (11 January 2016);
- [treatment of salivary gland cancer](/en/medicines/human/orphan-designations/eu-3-18-1995) (21 March 2018);
- [treatment of glioma](/en/medicines/human/orphan-designations/eu-3-18-2097) (19 November 2018);
- [treatment of papillary thyroid cancer](/en/medicines/human/orphan-designations/eu-3-18-2098) (19 November 2018).

Vitrakvi was withdrawn from the Community register of orphan medicinal products in July 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Vitrakvi

- [EMEA-001971-PIP02-16-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001971-pip02-16-m04)
- [EMEA-001971-PIP03-18-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001971-pip03-18-m02)
- [PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib (ON-TRK) - post-authorisation study](https://catalogues.ema.europa.eu/study/44357)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/08/2025

## Share this page

[Back to top](#main-content)